TriSalus Life Sciences (NASDAQ:TLSI) Director Purchases $151,800.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom acquired 60,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were bought at an average cost of $2.53 per share, with a total value of $151,800.00. Following the acquisition, the director directly owned 147,555 shares in the company, valued at approximately $373,314.15. The trade was a 68.53% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

TriSalus Life Sciences Trading Up 13.1%

Shares of NASDAQ:TLSI traded up $0.35 during trading on Monday, reaching $3.03. The company’s stock had a trading volume of 773,435 shares, compared to its average volume of 276,402. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58. TriSalus Life Sciences, Inc. has a 12 month low of $2.20 and a 12 month high of $7.95. The firm’s 50 day simple moving average is $4.18 and its two-hundred day simple moving average is $5.13. The stock has a market capitalization of $185.77 million, a PE ratio of -2.15 and a beta of 0.56.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $13.21 million during the quarter, compared to the consensus estimate of $13.20 million. On average, research analysts predict that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On TriSalus Life Sciences

Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in shares of TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of TriSalus Life Sciences during the second quarter worth approximately $47,000. Invesco Ltd. purchased a new position in shares of TriSalus Life Sciences during the fourth quarter worth approximately $72,000. Abel Hall LLC purchased a new position in shares of TriSalus Life Sciences during the fourth quarter worth approximately $73,000. Finally, HighMark Wealth Management LLC bought a new position in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $75,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TLSI has been the subject of a number of analyst reports. Weiss Ratings downgraded shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Lake Street Capital reduced their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Finally, Canaccord Genuity Group reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.50.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.